New drug ALN-6400 targets HHT bleeding in early trial
NCT ID NCT06659640
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 33 times
Summary
This study tests a new drug called ALN-6400 for hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The trial has two parts: first, healthy volunteers get a single dose to check safety; then, HHT patients get multiple doses to see if it reduces bleeding. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
Clinical Trial Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Clinical Trial Site
RECRUITINGSt Louis, Missouri, 63110, United States
-
Clinical Trial Site
RECRUITINGChapel Hill, North Carolina, 27514, United States
-
Clinical Trial Site
RECRUITINGCamperdown, 2050, Australia
-
Clinical Trial Site
RECRUITINGParkville, 3050, Australia
-
Clinical Trial Site
RECRUITINGMount Royal, H3P 3P1, Canada
-
Clinical Trial Site
RECRUITINGToronto, M5B 1W8, Canada
-
Clinical Trial Site
RECRUITINGBordeaux, 33000, France
-
Clinical Trial Site
RECRUITINGBron, 69500, France
-
Clinical Trial Site
RECRUITINGHomburg, 66421, Germany
-
Clinical Trial Site
RECRUITINGL'Hospitalet de Llobregat, 8907, Spain
-
Clinical Trial Site
RECRUITINGBirmingham, Alabama, 35233, United States
-
Clinical Trial Site
RECRUITINGCypress, California, 90630, United States
-
Clinical Trial Site
RECRUITINGGainesville, Florida, 32608, United States
-
Clinical Trial Site
RECRUITINGIndianapolis, Indiana, 46260, United States
Conditions
Explore the condition pages connected to this study.